JP2012516315A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516315A5
JP2012516315A5 JP2011546961A JP2011546961A JP2012516315A5 JP 2012516315 A5 JP2012516315 A5 JP 2012516315A5 JP 2011546961 A JP2011546961 A JP 2011546961A JP 2011546961 A JP2011546961 A JP 2011546961A JP 2012516315 A5 JP2012516315 A5 JP 2012516315A5
Authority
JP
Japan
Prior art keywords
aqueous composition
nitric oxide
composition according
nitrite
component comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516315A (ja
Filing date
Publication date
Priority claimed from GBGB0901456.4A external-priority patent/GB0901456D0/en
Application filed filed Critical
Publication of JP2012516315A publication Critical patent/JP2012516315A/ja
Publication of JP2012516315A5 publication Critical patent/JP2012516315A5/ja
Pending legal-status Critical Current

Links

JP2011546961A 2009-01-29 2010-01-22 乾癬の処置 Pending JP2012516315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0901456.4A GB0901456D0 (en) 2009-01-29 2009-01-29 Treatment of psoriasis
GB0901456.4 2009-01-29
PCT/GB2010/050091 WO2010086637A1 (en) 2009-01-29 2010-01-22 Treatment of psoriasis

Publications (2)

Publication Number Publication Date
JP2012516315A JP2012516315A (ja) 2012-07-19
JP2012516315A5 true JP2012516315A5 (cg-RX-API-DMAC7.html) 2013-02-14

Family

ID=40469254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546961A Pending JP2012516315A (ja) 2009-01-29 2010-01-22 乾癬の処置

Country Status (11)

Country Link
US (1) US20110287113A1 (cg-RX-API-DMAC7.html)
EP (1) EP2391356A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012516315A (cg-RX-API-DMAC7.html)
KR (1) KR20110120287A (cg-RX-API-DMAC7.html)
CN (1) CN102369004A (cg-RX-API-DMAC7.html)
AU (1) AU2010209455A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007543A2 (cg-RX-API-DMAC7.html)
CA (1) CA2750758A1 (cg-RX-API-DMAC7.html)
GB (1) GB0901456D0 (cg-RX-API-DMAC7.html)
RU (1) RU2011135741A (cg-RX-API-DMAC7.html)
WO (1) WO2010086637A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2678069A4 (en) * 2011-02-25 2015-03-25 Univ Windsor DEVICE FOR CONTROLLED RELEASE OF TOPICAL STAIN OXIDE
EP3113849B1 (en) 2014-02-26 2019-06-12 Luma Therapeutics, Inc. Ultraviolet phototherapy apparatus
ITUB20154719A1 (it) * 2015-10-21 2017-04-21 Glano Tech Ltd Formulazione per il rilascio di ossido nitrico
KR20180134856A (ko) 2016-02-09 2018-12-19 루마 세러퓨틱스 인코포레이티드 광선요법에 의해 건선을 치료하기 위한 방법, 조성물 및 장치
US10716805B2 (en) * 2018-03-19 2020-07-21 Glanotech Limited Formulation for release of nitric oxide
CN114585347A (zh) * 2019-10-07 2022-06-03 香榭有限公司 用于将一氧化氮递送至皮肤的组合物
GB2588748A (en) * 2019-10-07 2021-05-12 Insense Ltd Composition for delivering nitric oxide to skin
KR102333779B1 (ko) * 2020-02-03 2021-12-03 주식회사 큐라젠 산화질소 플라즈마를 이용한 돌출형 폴리우레탄 드레싱폼 및 그 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
US7052711B2 (en) * 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
DE60142337D1 (de) 2000-06-15 2010-07-22 First Water Ltd Verfahren zur herstellung von hydrogelzusammensetzungen und dadurch hergestellten hydrogelzusammensetzungen
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
ATE329628T1 (de) 2002-04-24 2006-07-15 Insense Ltd Wundauflage enthaltend ein oxidoreduktase-enzym in hydratiertem zustand
US20040062793A1 (en) * 2002-07-05 2004-04-01 Dyke Mark Van Tissue defect dressings comprising proteinaceous networks
US20070059351A1 (en) * 2003-10-17 2007-03-15 Murrell George A C Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
BRPI0606829A2 (pt) * 2005-02-11 2009-07-21 Nolabs Ab dispositivo configurado, processo para fabricação de dispositivo configurado, usos de polìmero eluente de óxido nìtrico(no), método de tratamento e uso de óxido nìtrico(no)
EP1846009A2 (en) * 2005-02-11 2007-10-24 NOLabs AB Improved device for application of medicaments, manufacturing method therefor, and method of treatment
EP1690558A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for treatment of diabetic disorders
GB0505035D0 (en) 2005-03-11 2005-04-20 Insense Ltd Improvements relating to skin dressings
EP1704876A1 (en) * 2005-03-24 2006-09-27 NOLabs AB Cosmetic treatment, device for performing said treatment and manufacturing method thereof
GB0616350D0 (en) * 2006-08-17 2006-09-27 Univ St Andrews Adsorption and release of nitric oxide in metal organic frameworks
WO2008048514A2 (en) * 2006-10-13 2008-04-24 Nitric Biotherapeutics, Inc. Topical nitric oxide as a treatment of autoimmune diseases
GB0715554D0 (en) 2007-08-09 2007-09-19 Insense Ltd Improvements relating to skin dressings

Similar Documents

Publication Publication Date Title
JP2012516315A5 (cg-RX-API-DMAC7.html)
DK2173391T3 (da) Forbedringer vedrørende hudforbindinger
RU2011135741A (ru) Лечение псориаза
DE602008004643D1 (de) 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperazin als verbindung mit kombinierter serotonin-aufnahme, 5-ht3- und 5-ht1a-aktivität zur behandlung von schmerzen oder restsymptomen bei depressionen im zusammenhang mt schlaf und kognition
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
DE602007012024D1 (de) Regelungsverfahren für die Eluierung von therapeutischen Wirkstoffen
WO2010091376A3 (en) Devices and methods for perfusion therapy
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
JP2012517420A5 (cg-RX-API-DMAC7.html)
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
WO2014191738A8 (en) Degradable haemostat composition
EA201390745A1 (ru) Активируемая пользователем автономная выполненная в едином корпусе система доставки лекарственного средства посредством ионофореза
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
BR112013019680A2 (pt) combinações compreendendo macitentana para o tratamento de glioblastoma multiforme
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications
EP2578232A4 (en) TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES
MX2017006227A (es) Sistema de administración de óxido nítrico y métodos de uso.